Recent advances in renal cell carcinoma (RCC) treatment highlight combination therapies, particularly immune checkpoint inhibitors (ICIs) with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs), which are now established as the standard first-line approach for clear-cell RCC and significantly improve overall survival rates (3, 4). The gene discussed is VEGFA; the disease is renal cell carcinoma.